je.st
news
Tag: merck
Merck Announces Fourth-Quarter 2013 Dividend
2013-07-24 21:35:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.43 per share on the companys common stock for the fourth quarter of 2013. Payment will be made on Oct. 7, 2013, to stockholders of record at the close of business on Sept. 16, 2013. About Merck Language: English Contact: MerckMedia:Kelley P. Dougherty, 908-423-4291orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: announces
dividend
merck
announces fourthquarter
Merck Announces FDA Acceptance of New Drug Application for Vorapaxar, Investigational Anti-Thrombotic Medicine
2013-07-24 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational anti-thrombotic medicine, vorapaxar, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Merck is seeking FDA approval of vorapaxar for the secondary prevention of cardiovascular events in patients with a history of heart attack and no history of stroke or transient ischemic attack (TIA). About Merck Language: English Contact: MerckMedia:Pamela Eisele, (908) 423-5042orPatrick Witmer, (267) 305-4910orInvestor:Carol Ferguson, (908) 423-4465orJustin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
medicine
drug
acceptance
Merck: FDA cancels panel meeting on surgery drug
2013-07-16 22:00:10| Biotech - Topix.net
Inc. said Tuesday that the Food and Drug Administration has cancelled a Thursday meeting to review its drug designed to help patients "wake up" after surgery with anesthesia.
Tags: meeting
panel
drug
surgery
Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection
2013-07-16 18:01:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, confirmed today that the U.S. Food and Drug Administration (FDA) has cancelled Thursdays discussion of sugammadex at the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). Sugammadex sodium injection is Mercks investigational medicine for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. Language: English Contact: MerckMedia:Pam Eisele, 908-423-5042Sarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: statement
meeting
committee
advisory
Merck & Co., Inc. (MRK) vs. Verizon Communications Inc. (VZ): Which...
2013-07-15 09:57:27| Telecom - Topix.net
Dividend stocks outperform non-dividend-paying stocks over the long run. It happens in good markets and bad, and the benefit of dividends can be quite striking -- dividend payments have made up about 40% of the market's average annual return from 1936 to the present day.
Tags: which
inc
communications
verizon
Sites : [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] next »